Journal
VIRUSES-BASEL
Volume 14, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/v14092025
Keywords
HIV-1; AIDS; Nef; MHC-I; latent viral reservoir; antiretroviral; Nef inhibitor
Categories
Funding
- National Institutes Health [AI152677, AI057083, AI102724, GM112516]
Ask authors/readers for more resources
This review focuses on the discovery of pharmacological inhibitors of the HIV-1 Nef accessory protein. Nef inhibitors not only suppress HIV-1 replication, but also restore sufficient MHC-I to the surface of infected cells to trigger a cytotoxic T lymphocyte response. Combining Nef inhibitors with other therapeutic approaches may provide a path to clearing viral reservoirs.
While antiretroviral drugs have transformed the lives of HIV-infected individuals, chronic treatment is required to prevent rebound from viral reservoir cells. People living with HIV also are at higher risk for cardiovascular and neurocognitive complications, as well as cancer. Finding a cure for HIV-1 infection is therefore an essential goal of current AIDS research. This review is focused on the discovery of pharmacological inhibitors of the HIV-1 Nef accessory protein. Nef is well known to enhance HIV-1 infectivity and replication, and to promote immune escape of HIV-infected cells by preventing cell surface MHC-I display of HIV-1 antigens. Recent progress shows that Nef inhibitors not only suppress HIV-1 replication, but also restore sufficient MHC-I to the surface of infected cells to trigger a cytotoxic T lymphocyte response. Combining Nef inhibitors with latency reversal agents and therapeutic vaccines may provide a path to clearance of viral reservoirs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available